Answers are grounded in this paper and cite their sources.
Background Transformation of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) is a recognized mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and is associated with poor clinical outcomes. The optimal treatment strategy for transformed SCLC remains uncertain. Case presentation We report a case of EGFR exon 21 mutant lung adenocarcinoma in a 48-year-old woman who developed SCLC transformation approximately 4 years after surgery and postoperative adjuvant therapy. Clinical course and treatment Following the identification of SCLC, the patient received multiple treatment regimens, including platinum–etoposide chemotherapy, osimertinib, and local radiotherapy. A subsequent biopsy in 2019 again demonstrated small cell carcinoma. Peripheral blood molecular testing identified EGFR L858R, TP53 p.C242F, and RB1 c.607 + 1G > A-alterations. The patient died of respiratory failure in January 2020, approximately 6 years after the initial diagnosis and 20 months after the identification of SCLC transformation. Conclusion This case illustrates the clinical challenges of SCLC transformation in EGFR-mutant lung adenocarcinoma after a prolonged postoperative interval. The longitudinal treatment course and molecular findings provide additional clinical observations relevant to the management of transformed SCLC, although the contribution of individual treatments cannot be determined from a single case.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: